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Objective: Sulfur mustard (SM) causes blisters on the human skin. These blisters delay
healing of the skin and make the victims more susceptible to infection. In vitro models
have been used for protection studies against SM injury, but study on wound healing
after SM exposure has not been explored. The purpose of this study was to test whether
the addition of exogenous growth factors could improve the rate of SM wound heal-
ing. Methods: The model consisted of normal human epidermal keratinocytes seeded
into 6-well plates, exposed to SM, and wounded (disruption of the cell monolayer)
with a sterile wounding instrument. Cells were then stained and images were captured
to measure percentage wound fill. Epidermal growth factor (EGF) and keratinocyte
growth factor (KGF) were tested in this model. Results: EGF (1 ng/mL) significantly
increased wound fill on all of the days tested (days 6, 9, and 12). KGF did not sig-
nificantly improve wound healing. Conclusions: EGF showed promise as a potential
therapy for SM-induced wounds. This in vitro model was a valuable tool for screen-
ing therapeutics before animal testing. These results will be used to develop a dressing
that can slowly release EGF on to a debrided wound bed to help speed the healing
process.
WOUND HEALING OVERVIEW
An understanding of normal wound healing is imperative for the development of an appro-
priate in vitro model for sulfur mustard (SM) injury. However, the topic of wound healing is
too complicated to be covered in its entirety in this article. Therefore, this article addresses
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only some of the key points of the predominant phases of wound healing to provide a brief
overview of this complex topic. Skin contains 2 main tissue layers, an epidermal layer of
stratifiedsquamousepitheliumconsistingof5differentsublayersandanunderlyingdermal
layer of connective tissue rich in collagen. Hair and glands are derived from the epidermis
but protrude deep into the dermal layer.1
Wound healing is a continuous and complex process that is generally characterized as
having 4 overlapping phases: coagulation, inflammation, proliferation, and remodeling.2
Coagulation begins immediately following injury. A clot consisting of platelets and fibrin
fibers is formed to maintain hemostasis, shield the wounded tissue, and serve as a scaffold
for cells migrating into the wound. The clot also serves as a reservoir of growth factors and
cytokines that attract inflammatory cells, such as neutrophils and monocytes, to the wound
site.1 Inflammation begins within minutes after the injury. Neutrophils clear out contami-
natingbacteriaandreleasecytokinestoactivatefibroblastsandkeratinocytes.Macrophages
phagocytize any remaining pathogens, debride the wound, and secrete growth factors and
cytokines that stimulate fibroblasts and endothelial cells.2 During the proliferative phase,
endothelial cells, fibroblasts, and keratinocytes proliferate and migrate into the wound to
repairvasculardamage,replacedestroyedtissue,andresurfacethewound.Endothelialcells
detach from undamaged blood vessels via collagenase, migrate into the wound, and prolif-
erate to restore vascular integrity.3 Dermal fibroblasts adjacent to the wound site proliferate
early after injury, and then around 3 or 4 days after injury, migrate into the wound clot and
lay down a matrix rich in collagen.1
Within hours after injury, keratinocytes begin to migrate into the wound. After
several days, migrating keratinocytes proliferate, form a protective monolayer over the
wound, and reestablish contact with the underlying basement membrane in a process called
epithelialization.3 This process is aided by contraction of the underlying connective tissue,
which brings the edges of the wound closer together. The keratinocytes then cease to prolif-
erate and migrate, but instead differentiate to form a new stratified epidermis attached to a
basal lamina.2 Proteases play an important role in epithelialization. They are thought to be
responsible for releasing keratinocytes from the basal lamina and for permitting leading-
edge keratinocytes to pass through and along the fibrin clot.1 During the remodeling phase
of wound healing, proteases remove excess collagen and matrix. Collagen fibers increase
in thickness and realign to give strength to the healing tissue. Remodeling may take up
to a year to complete, but will never result in tissue as strong as the original uninjured
tissue.2
THE SM THREAT
Mustard was first used in World War I and was responsible for an estimated 80% of all
chemical casualties.4 Recent terrorist attacks and the use of SM in military conflicts such
as the Iran-Iraq War of the 1980s have stressed the need for the development of pharmaceu-
tical treatments for the clinical management of chemical warfare agent casualties. Current
treatments for SM injuries include deroofing, debridement, irrigation, topical antibiotics,
and sterile dressings.4,5 However, these treatments need to be improved to eliminate in-
fections, enhance cosmetic outcomes, and improve wound healing. Graham et al5 have
comprehensively reviewed strategies for developing improved therapies for cutaneous SM
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injuries. Appropriate in vitro screening techniques, before animal testing, may speed up the
development of clinical treatments.
Mustard is a persistent, oily chemical agent that can cause injury to the eye, airway,
and skin. Initial clinical symptoms in the skin include erythema followed by vesication,
the extent of which is dependent on the level of exposure to SM. SM (2,2 -dichlorodiethyl
sulfide) reacts with nucleophilic sites such as DNA, proteins, and membrane components,
and several mechanisms for damage have been suggested.6 The basal epidermal cell is a
primary target for SM.6,7 Ultrastructural studies using transmission and scanning electron
microscopy were performed on SM-treated hairless guinea pig skin and cultured human
keratinocytes. These studies revealed that the nucleus, plasma membrane, and anchoring
filaments of the epidermal basal cells were damaged. This damage led to separation of the
epidermis from the underlying dermis and production of a subepidermal microblister in the
skin of the hairless guinea pig.4,7
IN VIVO CUTANEOUS WOUND HEALING MODELS FOR SM
Appropriate in vivo and in vitro models are critical for the development of clinical treat-
ments. These models are especially important for developing SM therapies because hu-
man clinical trials cannot be conducted for ethical reasons. A number of animal models
have been used to study SM-induced cutaneous lesions, including the hairless guinea pig,
mouse ear, hairless mouse, and the weanling pig. Although no one animal model is perfect
for studying all aspects of human blister formation, these models have proven valuable
for studying various aspects of SM injury.8 In general, the mouse ear seems to be the
most resource-efficient animal model for initial drug screening. Pig skin is most simi-
lar to human skin and appears to be the best animal model for testing drugs, studying
histopathology, and developing wound healing therapies.5,8 In particular, weanling pigs
have been used extensively as an animal model for efficacy testing of candidate treat-
ment regimens.5,9,10 They were used to test laser debridement,11 sterile dressings, and
allograft materials.12 In addition, several noninvasive bioengineering techniques were de-
velopedtodeterminelesiondepth13,14 andtomonitorwoundhealingprogressfollowingSM
exposure.15
However, animal models can be time consuming and costly. An in vitro wound healing
modelcouldbeusedasafirst-linescreenbeforeanimaltesting,potentiallyminimizingcost,
reducing animal use, and expediting fielding of wound healing products. Complementary
in vitro and in vivo studies could provide stronger evidence than in vivo studies alone that
a candidate therapy should be used to treat an SM injury.
IN VITRO CUTANEOUS WOUND HEALING MODELS FOR SM
Current in vitro cutaneous models focus on understanding the biochemical mechanisms of
SM-inducedcutaneousinjurywiththeultimategoalofdevelopingmedicalcountermeasures
to prevent blister formation. Human epidermal keratinocytes are widely used to model the
cytotoxic effects of SM on basal epidermal cells16 and have been used to study a number of
cellular processes, including protease induction,17 apoptosis,18 and metabolism.19 Primary
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rat keratinocyte cultures20 and a number of immortalized human skin cell lines, includ-
ing G361, SVK14, HaCaT, and NCTC 2544, have also been used to study SM toxicity.21
Organ culture of full-thickness human skin explants exposed to SM were used to identify
mediators of the inflammatory response.22 Another research team used bioengineered hu-
man skin grafted to nude mice to study the early events in SM-induced cutaneous injury.
This bioengineered skin demonstrated many of the alterations found in animal models of
cutaneous SM injury, but the latest time point in which it was evaluated was 24 hours.23
Medical prophylactics are critical to protecting soldiers and civilians from an SM
attack. However, not everyone in the attack will be fully medically prepared to prevent
SM injury. There will be victims even if the prophylactic is considered 100% medically
effectivebecause,inreality,consumeruseerrorswillmaketheprophylacticlessthan100%
effective. One in vitro model was developed to investigate the mechanisms involved in
delayed healing of SM wounds. This model consisted of a 3-dimensional culture of human
fibroblasts in collagen gel surrounded by normal human keratinocytes and elucidated some
of the dermal-epidermal interactions in normal skin.24 However, this model was not used
to test therapies to combat delayed healing of SM wounds.
The purpose of this study was to test whether the addition of extrinsic growth fac-
tors could help improve the rate of SM wound healing. Epidermal growth factor (EGF)
and keratinocyte growth factor (KGF) were evaluated in an in vitro wound healing
model.
MATERIALS AND METHODS
Cell cultures
Normal human epidermal keratinocytes (NHEKs) were obtained from Dr William Smith’s
laboratory at the US Army Medical Research Institute of Chemical Defense from commer-
cialsources(CambrexBioscience,Walkersville,Md),aspreviouslydescribed.25 Cells(third
passage) were seeded into 6-well plates (Corning Corporation, Corning, NY) and grown to
30 to 40% confluency in keratinocyte growth medium (KGM, Cambrex Bioscience).
SM wound production
Cellswereexposedto0,5,10,25,50,or100μMofSM,inKGM,inachemicalsuretyhood
for1hour.16 Cellsweretransferredtoanincubatorforanadditional2hoursofSMexposure
at 37˚C and 5% CO2 and then used in the wound healing model. A 3-mm wide wound
(disruption of the cell monolayer) was created with a sterile wounding instrument.26,27
Cells were rinsed, and the wounded area was examined microscopically to ensure that
cellular debris was removed. Wounds were marked on the bottom of the plate with a blue,
ultrafine point permanent marker (Sharpie, Sanford Corporation, Oak Brook, Ill), and the
wells received fresh media (with or without growth factor treatment).
Growth factor treatments
EGF (#1376454, Roche Molecular Biochemicals, Indianapolis, Ind) was resuspended in
sterile H2O and diluted to its final concentrations (1, 10, or 20 ng/mL) in KGM. KGF
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(recombinant human [rh] KGF, #N000173, Amgen, Inc., Thousand Oaks, Calif) was resus-
pended in sterile H2O, diluted in PBS containing bovine serum albumin (0.1%) to prevent
degradation, and diluted to its final concentrations (10, 50, or 100 ng/mL) in KGM. For
both growth factors, half volume media changes (with fresh growth factor) were performed
daily. Control NHEKs received daily half volume medium changes with KGM alone. Half
volume media changes were conducted to provide fresh growth factor to cells and to re-
duce disruption of the cellular environment within the well in the event that cells secreted
autocrine factors.
Crystal violet stain
Cells were stained with the cytoplasmic stain crystal violet (#C3886, Sigma-Aldrich, St
Louis, Mo), as previously described.28 Briefly, cells were fixed with 4% paraformaldehyde,
rinsed 3 times with 0.1 M of phosphate buffer, and stained for 1 minute in 0.1% crystal
violet (wt/vol) in deionized water. Cells were washed with deionized water and were air
dried.
Wound ﬁll measurements
Images of stained cells were captured using a digital camera (Coolpix, Nikon Instrument
Inc., Lewisville, Tex) and a dissecting microscope (#SZX12, Olympus, Center Valley, Pa).
ImageswerethenanalyzedwithImage-ProPlus5.0software(MediaCybernetics,Bethesda,
Md) to determine percentage wound fill. Each image was analyzed 3 times.
Statistical analyses
Data are reported as mean ± standard error of the mean (SEM). Statistical significance
was defined as P ≤ .05 for all tests. Analyses were conducted using Statistical Analysis
System software (SAS Institute, Inc., Cary, NC). Depending on the number of variables
involved in a particular study (ie, SM concentration, drug treatment, day cells stained), a
2-sample t test or an analysis of variance was conducted. A Tukey test was then used to
compare the pairs of treatment groups. See figure legends for the specific statistical test
conducted.
RESULTS
Test of EGF
EGF was tested in the in vitro wound healing model. In the first study, NHEK cells were
exposed to 5 μM of SM and treated daily with KGM containing 0, 1, 10, or 20 ng/mL of
EGF (Fig 1). For the cells exposed to 0 μM of SM, there was a 6% increase in wound fill
in cells that received EGF versus those NHEKs that did not (P ≤ .05). For cells exposed
to 5 μM of SM, data suggested that the cells treated with 1 ng/mL of EGF had the high-
est percentage wound fill, but this difference was not found to be statistically significant
(P ≤ .05).
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Figure 1. NHEK cells exposed to 5 μM of SM and treated with EGF. Cells were treated daily
with 0, 1, 10, or 20 ng/mL of EGF and stained with 0.1% crystal violet 6 days after wounding.
For 0 μM of SM, a significant difference∗ (P ≤ .05) in wound fill was observed between the cells
treated with 0 ng/mL of EGF and the 1, 10, and 20 ng/mL of EGF groups. For 5 μM of SM, cells
treatedwith1ng/mLofEGFhadthegreatestpercentageofwoundfill,butnostatisticallysignificant
differences were observed between the EGF treatment groups. Data points represent mean values ±
SEM of 3 determinations. A 1-factor ANOVA was used to compare treatment groups at each SM
concentration.
In a second study, the most promising EGF concentration (1 ng/mL) was tested after
exposure to 0, 5, 10, 25, or 50 μM of SM (Fig 2). Regardless of the SM concentration
tested, NHEK cells treated with 1 ng/mL of EGF had significantly more wound fill than
those cells that received cell culture medium without 1 ng/mL of EGF, at all days tested
(days 6, 9, and 12).
Test of KGF
KGF was tested in the in vitro wound healing model. NHEK cells were exposed to 0, 10,
or 100 μM of SM and treated daily with KGM containing 0, 10, 50, or 100 ng/mL of KGF
(Fig3).Asignificantdifferenceinpercentagewoundfillwasobservedbetween0and10μM
ofSMonday6,regardlessoftheKGFconcentrationtested.Thecellsexposedwith10μMof
SMhad15%to32%lesswoundfillthancellsnotexposedtoSM.Nosignificantdifferences
between KGF doses were observed for day 6. A significant difference in percentage wound
fill was also observed between 10 and 100 μM of SM exposed cells on day 9. The cells
exposed with 100 μM of SM had 34% to 71% less wound fill than those exposed with
10 μM of SM. The data suggest that following exposure to 10 μM of SM, the addition of
KGF at any concentration tested improved wound healing compared with untreated control
cells.However,nosignificantdifferencesbetweenKGFconcentrationswerenotedforday9
(P ≤ .05).
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Figure 2. Woundfilltime-coursestudyforNHEKcellsexposedtovariousconcentrationsofSMand
treatedwith1ng/mLofEGF.Cellswereexposedto0,5,10,25,or50μMofSM,treateddailywith0
or 1 ng/mL of EGF, and stained with 0.1% crystal violet at 6 (a), 9 (b), or 12 (c) days after wounding.
A significant difference* was observed between the 2 treatment groups, 0 and 1 ng/mL of EGF, on
days 6, 9, and 12. However, no significant interactions were observed between SM concentrations
andEGFdoses,soitcannotbespecificallystatedthattherewasasignificantdifferencebetweenEGF
doses at a particular SM concentration (ie, 0, 5, 10, 25, or 50 μM of SM). Significant differences
betweenSMconcentrations,† regardlessofEGFdose,wereobservedateachday.(a)Forday6,0μM
of SM† had significantly different wound fill than 5, 10, 25, and 50 μM of SM. In addition, 5 μMo f
SM† had significantly different wound fill than 10, 25, and 50 μM of SM. (b and c) For days 9 and
12, 5 μMo fS M † had significantly different wound fill than 10, 25, and 50 μM of SM and 10 μM
of SM† had significantly different wound fill than 25 and 50 μM of SM. Data points represent mean
values ± SEM of 6 determinations from 2 separate experiments. A 2-factor ANOVA at each staining
day was used to compare the SM concentrations and the 2 EGF doses. Statistical significance was
defined as P ≤ .05 for all tests. (d) Summary graph of parts (a)–(c). (Continued on next page).
DISCUSSION
The purpose of this study was to determine whether the addition of extrinsic growth factors
could improve the rate of wound healing following SM exposure. NHEKs were chosen
because they appear to be a good model for basal epidermal cells,29 a principal target for
SM-induced skin lesions.6,30 The 3-hour SM exposure time (1 hour in the hood and 2 hours
in the incubator) was chosen to make this model as clinically relevant as possible and to
meet laboratory safety standards for working with SM. Laboratory specimens must remain
in a chemical fume hood for a minimum of 1 hour after SM exposure to off-gas, per safety
regulations.Aftertheinitial1hour,cellsareplacedinanincubatorat37˚Cforanadditional
2hoursforatotalSMexposureof3hours.Erythemabegins1to24hourspost-SMexposure
and is characteristically seen 4 to 8 hours after SM exposure.4 Many victims do not realize
they were exposed to SM and do not take corrective action until erythema appears. The
3-hour SM exposure time for the in vitro model correlates with what is seen clinically.
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Figure 2. (Continued).
The SM concentrations selected for these experiments were based on a previous study.
A liquid droplet of about 10 μg of SM produces vesication on the skin.4 Previous studies
determined lethal and sublethal concentrations of SM on cultured HEKs.16,19 The SM
concentrationsusedinthisstudywereselectedonthebasisofpersonalcommunicationwith
Dr Bill Smith of US Army Medical Research Institute of Chemical Defense, as described
previously. This study showed that SM demonstrated a concentration-dependent decrease
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Figure 2. (Continued).
in wound fill by NHEK cells as the SM concentration increased. In general, regardless of
SM exposure, wound fill increased from day 3 to day 6, reached its highest values at day 6,
remained constant or slightly decreased at day 9, and finally decreased at day 12.31
The daily treatment regimen was selected on the basis of the frequency with which
one might change a dressing on a small wound. Autocrine factors could easily be removed
in a cell culture model if a complete media change was performed daily. For this reason,
half volume media changes were conducted to provide fresh growth factors to cells and to
reduce disruption of the cellular environment within the well.
AcandidategrowthfactorfortheinvitrowoundhealingmodelisEGF(β-urogastrone).
EGF is expressed in cells by various adult tissues and its production is increased by
testosterone and decreased by estrogen.32 EGF was shown to increase the motility of ker-
atinocytes and many other cell types.33 Keratinocyte colonies treated with EGF had an
8-fold greater rate of increase of colony radius than untreated control colonies. The colony
growth effect of EGF was reported to be because of EGF’s ability to increase the rate
of cell migration in the cells located along the peripheral border of the colony.34 EGF
induced migration and contraction of primary cultures of human keratinocytes and stimu-
lated the mitogen-activated protein kinase signal transduction pathway, a requirement for
reepithelialization.35
In normal human skin, high concentrations of EGF receptor were found on basal
keratinocytes.33 EGF receptors are measured clinically (testing available from several ref-
erence laboratories such as Quest Diagnostics and Mayo Medical Laboratories), but serum
EGF is not routinely measured clinically (Dr Joseph Wood, PhD, MD, Endocrine, Diabetes,
and Metabolism Service, Dwight D. Eisenhower Army Medical Center, Fort Gordon, Ga,
written communication, 2007). One research study did evaluate EGF serum levels by en-
zyme immunoassay in schizophrenic and control patients. The serum EGF concentration
was measured at 554 ± 350 pg/mL in the 14 control patients tested.36 In comparison, this
study tested 1000, 10,000, and 20,000 pg/mL of exogenously added EGF (concentrations
were based on manufacturer’s recommendations for serum-free cell culture systems).
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Figure 3. Wound fill time-course study for NHEK cells exposed to various concen-
trations of SM and treated with 0, 10, 50, or 100 ng/mL of KGF. Cells were exposed
to 0, 10, or 100 μM of SM, treated daily with the appropriate KGF concentration, and
stained with 0.1% crystal violet at 6 (a) or 9 (b) days after wounding. (a) A significant
difference∗ in percentage wound fill was observed between 0 and 10 μMo fS Mo n
day 6. No significant differences between KGF doses were observed for day 6. (b) A
significant difference∗ in wound fill was observed between 10 and 100 μMo fS Mo n
day 9, but no significant differences were noted between the KGF doses. Data points
represent mean values ± SEM of 3 determinations. A 2-factor ANOVA was used to
comparethetreatmentgroupsandSMconcentrationsateachday,followedbyaTukey
post hoc comparison of pairs of treatment groups. Statistical significance was defined
as P ≤ .05 for all tests.
In this study, NHEK cells treated with 1 ng/mL of EGF following SM exposure had
significantly greater wound fill than untreated, SM-exposed NHEK cells. This finding is
consistent with other in vitro, in vivo, and clinical studies. Best growth of oropharyngeal
keratinocytes was achieved with an EGF concentration of 0.15–1.5 ng/mL.37 In animal
studies,topicalapplicationofbiosyntheticEGFacceleratedepidermalregenerationinsplit-
thickness wounds in the pig.38 A rat burn study demonstrated that EGF administration
acceleratedhealingoftheburnwoundontheskin.39 TopicalapplicationofrhEGFointment
promoted wound healing by myofibroblast proliferation and collagen synthesis in the rat.40
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In humans, a phase III clinical trial conducted in India demonstrated the safety and efficacy
of using an rhEGF gel (REGEN-D 150, Bharat Biotechs International Limited, Hyderabad,
India, 150 mg/g) to treat diabetic foot ulcers.41 A phase IV , postmarketing surveillance
study of REGEN-D 150 confirmed faster healing of diabetic foot ulcers and an increase
in percentage of patients cured, and recorded no adverse events in patients enrolled in the
study.42
KGF/fibroblast growth factor 7 is another candidate for clinical applications involving
proliferation and stimulation of epithelial cells.43 KGF promoted cell motility in an in vitro
wound healing model of alveolar epithelium.44 In addition, normal human keratinocytes
treated with a combination of KGF and the predominant glycosaminoglycan in skin, der-
matansulfate,werestimulatedtogrowinculture.45 HumanKGFtopicallyappliedtoporcine
models of partial- and full-thickness wounds stimulated the rate of reepithelialization.46 A
World Health Organization reference standard for KGF was recently established in 2006,47
but routine KGF clinical testing is not currently available (Dr Joseph Wood, PhD, MD, En-
docrine, Diabetes, and Metabolism Service, Dwight D. Eisenhower Army Medical Center,
Fort Gordon, Ga, written communication, 2007).
In vitro, KGF was tested at concentrations of 1, 10, and 100 ng/mL in bovine corneal
woundculturesovera5-dayperiod.Atday2afterwounding,bovinecornealwoundstreated
with 100 ng/mL of KGF had significantly greater reepithelialization than untreated control
corneas. However, lower doses of KGF had no effect, nor did the 100 ng/mL of KGF dose,
after the day 2 time point. This study also demonstrated that 1 ng/mL of KGF, but not 10
and 100 ng/mL of KGF, stimulated bovine keratinocyte migration when evaluated 8 hours
after wounding. Later time points were not included in this study.48 This study of human
keratinocytes tested 0–100 ng/mL of KGF at days 6 and 9 after wounding and reported
no significant improvement in wound fill. These data are consistent with the later time
points of the bovine corneal wound experiments. Perhaps, if KGF testing had been done at
earlier time points for this study, KGF-stimulated wound fill improvement might have been
detected in the human keratinocyte wound-healing model.
Clinically,KGFisapromisingmitogen.HumanrecombinantKGF,commerciallyavail-
able as palifermin (Kepivance, Amgen, Inc.), received US Food and Drug Administration
approvalforthetreatmentofsevereoralmucositisinpatientsreceivingintensivechemother-
apy followed by stem cell transplant for hematologic cancers.49 Palifermin was shown to
reduce both the duration (6 days vs 9 days, P < .001) and incidence (63% vs 98%, P < .001)
ofgrade3or4oralmucositisascomparedwiththeplacebogroup.50 Paliferminhasalsohad
success in phase I and II clinical trials for treating mucositis in patients with solid tumors
who receive chemotherapy with or without radiation therapy.49 The Mucositis Study Group
oftheMultinationalAssociationofSupportiveCareinCancerandtheInternationalSociety
for Oral Oncology updated their clinical practice guidelines for the prevention and treat-
mentofmucositis.51 Onechangefromtheoriginal2004guidelines52 istherecommendation
for the use of palifermin for oral mucositis associated with stem cell transplantation. The
panel recommends a dose of 60 μg/kg of palifermin per day for 3 days before conditioning
treatment and 3 days after transplantation to prevent oral mucositis.51This study of human
keratinocytes did not test KGF as a prophylaxis to SM-induced injury, but this concept will
be incorporated into future studies.
One limitation of this study is that it addresses only the effects of SM on 1 cell
type involved in the wound healing process. Keratinocytes may be a principal target for
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SM-induced skin lesions,6,30 but other cell types are destroyed in chronic SM wounds.
Migrating and proliferating cell types involved in wound healing, such as fibroblasts and
endothelial cells, are also good candidates for SM in vitro studies. A bioengineered human
skin model is currently being used to identify early events in SM-induced skin injuries.23
Further development of this model could lead to a human skin model for studying wounds
created by SM.
Another limitation of this study is that it does not address the issue of proteases. In a
study of chronic and acute wound fluids, a 30-fold elevation of matrix metalloproteinase
activity was observed in chronic wounds in comparison with acute wounds. There was
also significantly higher degradation of exogenously added EGF in chronic wounds than
acute wounds.53 SM stimulated an approximately 80-KDa serine protease release in cul-
tured NHEKs. Protease activity at the dermal-epidermal junction is thought to lead to skin
degradation, fluid accumulation, and blister formation.17 Exogenous growth factors added
to this protease-rich environment could be destroyed before they could improve wound
healing. Adding protease inhibitors, along with growth factors, to a wound could indirectly
protect the growth factors long enough to improve wound healing. In fact, guinea pigs
pretreated with the protease inhibitor doxycycline before SM intratracheal intoxication dis-
playedlessinflammationandhistologicalepitheliallesions.54 SM-inducedproteaseactivity
could destroy exogenously added growth factors before they could improve wound healing.
Cell-controlled delivery of KGF via a fibrin gel improved wound healing both in an in vitro
model of lung epithelium and in an in vivo full-thickness wound model (hybrid of human
bioengineered skin transplanted on to athymic mice) as compared with the same models
that received topically applied KGF.55 Protection and proper delivery are imperative for the
growth factor to exert its effect. For these reasons, future experiments will be conducted
with a concomitant use of antiproteases and growth factors in various delivery modes.
In conclusion, EGF showed promise in improving healing of SM skin injuries. KGF
may exert its effects earlier in the wound healing process. This in vitro wound healing
modelwasausefultoolforevaluatingtherapeuticsforcutaneousSMinjuriesbeforeanimal
testing. The information gained from this study will be used to develop a dressing that can
slowly release, among other things, EGF on to a debrided wound to help speed the healing
process. Protease inhibitors will also be considered in the development and/or application
of this dressing.
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